A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants, especially the Omicron variant, have impaired the efficacy of existing vaccines and most therapeutic antibodies, highlighting the need for additional antibody-based tools that can efficiently neutralize emerging SAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Mengqi, Chen, Xiangyu, Zhu, Yanzhi, Dong, Xiaoqing, Liu, Yan, Qian, Zhaohui, Ye, Lilin, Liu, Pinghuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400488/
https://www.ncbi.nlm.nih.gov/pubmed/35916510
http://dx.doi.org/10.1128/jvi.00775-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400488/
https://www.ncbi.nlm.nih.gov/pubmed/35916510
http://dx.doi.org/10.1128/jvi.00775-22

Ejemplares similares